In summary, evidence suggests that GLUT1, HK2, LDHA, MCT1, PKM2 and PFK1 could become potential biomarkers, either diagnostic or prognostic, in breast cancer, depending on the molecular subtypes and treatment involved. The gene discussed is PFKM; the disease is breast carcinoma.